Showing 21-30 of 327 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Assessing and mitigating T cell recognition of iPSC derived endocrine cells in Type 1 Diabetes | Benaroya Research Institute at Virginia Mason | Eddie James | Cures | 01-June-2024 to 31-May-2026 | $500,000.00 |
| Cooperative harmonization and validation of an islet-specific AIM assay | Benaroya Research Institute at Virginia Mason | Karen Cerosaletti | Cures | 01-February-2024 to 31-January-2026 | $299,998.00 |
| Early immune and beta cell monitoring predicts treatment response | Benaroya Research Institute at Virginia Mason | S. Alice Long | Cures | 01-August-2019 to 31-July-2025 | $2,499,814.79 |
| New lipid biomarker to predict early risk for Type 1 diabetes | Beth Israel Deaconess Medical Center Inc | Barbara Kahn | Cures | 01-September-2024 to 31-August-2027 | $899,997.53 |
| Integration of Slow-Release A1AT-loaded Nanoparticles for Enhanced Cell Therapy in Type 1 Diabetes | Beth Israel Deaconess Medical Center Inc | Giuseppe Pettinato | Cures | 01-October-2024 to 31-July-2026 | $200,000.00 |
| Determining the role of new genes that may be involved in Type 1 Diabetes Pathogenesis | Beth Israel Deaconess Medical Center Inc | Ismail Syed | Cures | 01-June-2024 to 31-October-2025 | $199,999.67 |
| Consulting Support for Continuity Biosciences | Biologics Consulting Group, Inc. | Diana Colleluori | Cures | 01-April-2025 to 31-August-2025 | $63,475.00 |
| Ad Hoc Consulting Support | Biologics Consulting Group, Inc. | Diana Colleluori | Cures | 01-July-2025 to 30-November-2025 | $61,475.00 |
| Engineered Nanobodies to Visualize and Direct Antigen-Specific Tolerance in T1D | Boston Children's Hospital | Novalia Pishesha | Cures | 01-March-2025 to 28-February-2030 | $999,999.00 |
| A wireless oxygen generating immune protection device to support long term cell transplantation for the treatment of Type I Diabetes | Boston Children's Hospital | Robert Langer | Cures | 01-August-2025 to 31-July-2028 | $2,481,286.98 |